The aim of this study was to evaluate the usefulness of serum (1,3)-beta-D-glucan (BDG) for earlier detection of breakthrough candidemia. We reviewed the medical records of patients with candidemia from January 2008 to March 2013. Serum BDG was measured by Wako turbidimetric assay. During the study period, a total of 147 cases of candidemia were identified, and 31 patients met the criteria for breakthrough candidemia. Serum BDG levels were measured in 25 patients with breakthrough candidemia and 67 patients with nonbreakthrough candidemia. Almost all of the patients with breakthrough candidemia had hematological malignancies. More candidemia were caused by non-C. albicans Candida in the breakthrough group than in the nonbreakthrough group (92.0% vs. 61.8%, p = .005). The median BDG value was significantly lower in breakthrough episodes than in non-breakthrough episodes (18.5 pg/ml vs. 90.4 pg/ml, p = .01). Moreover, BDG values under the cutoff was significantly higher in patients with breakthrough candidemia than in those with nonbreakthrough candidemia (44% vs. 19%, p = .03). In summary, BDG alone was insufficient to detect breakthrough candidemia, and candidemia could occur in patients being treated with antifungal agents, even when the BDG value was under the cutoff value.
Introduction
Candidemia is one of the most common nosocomial bloodstream infections and is associated with high morbidity and mortality [1, 2] . When such infections develop during systemic antifungal therapy, it is known as breakthrough candidemia. Previously, several studies have shown the characteristics and risk factors in patients with breakthrough candidemia [3] [4] [5] , but there were no data for patients with breakthrough candidemia as compared with nonbreakthrough (de novo) candidemia focusing on serological biomarkers.
Recently, (1,3)-beta-D-glucan (BDG) has been developed as an early and rapid serologic biomarker for detecting invasive fungal infections, and its effectiveness for detecting invasive candidiasis was shown in several articles [6, 7] . The aim of this study was to evaluate the effectiveness of BDG in detecting breakthrough candidemia as compared with that in nonbreakthrough candidemia.
Materials and methods
All episodes of candidemia that occurred between January 2008 and March 2013 at Toranomon Hospital (Tokyo, Japan, 890 beds) and Toranomon Hospital Kajigaya (Kanagawa, Japan, 890 beds) were identified. Medical records were reviewed to identify the underlying malignancies (hematological malignancies or solid tumors), the pretreatment antifungal agents, the value of BDG, and all-cause 30-day mortality. We also reviewed the administration of systemic corticosteroids, the administration of immunosuppressive agents, the presence of neutropenia, central-venous catheter insertion, mechanical ventilation usage, and kinds of comorbidity. The value of BDG was examined at the same time of taking blood culture or within 7 days after taking blood cultures that turned out to be positive for Candida species. This study included the patients whose serum BDG were measured during this period. This investigation was approved by the Human Ethics Review Committee of Toranomon Hospital.
Definitions
Candidemia was defined as the isolation of any Candida species from ≥1 set of blood culture from a patient who had signs and symptoms of infection. Breakthrough candidemia was diagnosed if a patient had received systemic antifungal therapy for over 7 days before finding the first positive blood culture [8] . A second episode of candidemia occurring in the same patient within 4 weeks of the first episode was counted as being the same episode [9] .
The administration of systemic corticosteroid or immunosuppressive agents was defined as their usage within a period of 4 weeks before the onset of candidemia. Chronic renal failure was defined as estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m 2 over 4 weeks before the onset of candidemia. Septic shock was defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation or requiring vasopressor agents [10] .
Identifications
Candida isolates were recovered on Sabouraud Dextrose agar (Nippon Becton Dickinson Company, Ltd, Japan) at 35
• C and identified to species level through the use of the Vitek or Vitek2 systems (bioMe´rieux, Marcy l'Etoile, France) for all germ-tube negative yeasts.
Serum BDG
The test used for measuring serum BDG was the Wako turbidimetric assay (Wako Pure Chemical Industries, Tokyo, Japan) [11] using the cut-off values for positivity recommended by manufacturer's instructions, i.e., the conventional cut-off value (11 pg/ml) [12] . In recipients of allogeneic hematopoietic stem cell transplantation, serum BDG values were routinely measured once a week. In other patients, serum BDG values were assessed after the isolated of yeast-like fungi or when clinical findings suggested a fungal infection.
Statistical analysis
Categorical variables were analyzed using χ 2 or Fisher exact test. The Mann-Whitney U test was performed to test the equality of continuous variables. In all analyses, the level of significance was set at α = .05. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics [13] .
Results

Characteristics of patients
A total of 147 cases of candidemia occurred during the study period, of which 31 patients met the criteria for infection with breakthrough candidemia. Serum BDG was measured within 7 days after obtaining positive blood cultures in 67 patients with nonbreakthrough candidemia and 25 with breakthrough candidemia. The general characteristics of the patients with breakthrough and nonbreakthrough candidemia included in the present study are shown in Table 1 . Those with breakthrough candidemia were significantly younger than those with nonbreakthrough candidemia (median age of 56 years vs. 72 years; p < .001).
The median body temperatures when specimens were obtained for blood cultures were taken were lower in breakthrough cases than in patients with nonbreakthrough infections (median: 38.3
of the patients with breakthrough candidemia had hematological disorders as their underlying diseases, while solid tumors were the most common underlying factor in those with nonbreakthrough candidemia. Moreover, neutropenia, systemic corticosteroid use, immunosuppressive agent use, and allogeneic hematopoietic stem cell transplantation were more common in breakthrough cases. The rate of diabetes mellitus, renal failure, hemodialysis, liver cirrhosis, mechanical ventilation, intensive care unit (ICU) settings, central-venous catheter insertion, and rate of septic shock were not statistically different between the two groups. 
Microbiology
Coinfection with two different Candida species was detected in one patient with nonbreakthrough candidemia (Candida albicans and Candida glabrata), but none was found in the breakthrough group. The causative Candida species is shown in Table 2 , with most cases of breakthrough candidemia caused by non-C. albicans Candida, especially C. parapsilosis and C. glabrata. The latter was the most common causative Candida species (7/25, 28%), in breakthrough cases, while Candida albicans was the most frequent etiologic agent in the nonbreakthrough cases (26/68, 38%). Candidemia caused by non-C. albicans Candida was more common in the breakthrough group than in the nonbreakthrough group (92.0% vs. 61.8%, p = .005).
Pretreatment antifungal agents
Information about pretreatment antifungal therapy was available for all 25 cases of breakthrough candidemia. Sixteen (64%) of the 25 episodes occurred during the use of micafungin (15 cases: prophylaxis, 1 case: preemptive therapy). Five patients (20%) received azoles (itraconazole in 2, voriconazole in 2, and fluconazole in 1 with fluconazole and itraconazole used as prophylaxis, and voriconazole as prophylaxis or preemptive therapy), and another 5 patients (20%) received liposomal amphotericin B (4 cases: preemptive therapy, 1 case: definitive therapy). In only one case, micafungin plus liposomal amphotericin B was used as a pretreatment antifungal agent.
The value of BDG
In most of the patients with breakthrough and nonbreakthrough candidemia, serum BDG value was measured during the period between obtaining specimens for blood cultures and within 48 hours of obtaining positive results. The distribution of the BDG values is shown in Figure 1 , and the number of positive or negative cases in both groups for each Candida species is presented in Table 2 . The The number in parentheses indicates the number of serum BDG positive/negative cases.
Figure 1.
The distribution of BDG in the two groups. The medians of the BDG value were 18.5 pg/ml in breakthrough candidemia and 90.4 pg/ml in nonbreakthrough candidemia. There was a statistically significant difference between the two groups (p = .01).
median BDG value was significantly lower in patients with breakthrough episodes than in those with nonbreakthrough episodes (18.5 pg/ml vs. 90.4 pg/ml, p = .01). Similarly, in the subgroup analysis of the cases in which the serum BDG value was measured during the period between obtaining specimens for blood cultures and within 48 hours of obtaining the positive results, the median BDG value was also significantly lower in patients with breakthrough episodes than in those with nonbreakthrough episodes (15.8 pg/ml vs. 107.6 pg/ml, p = .01). In terms of the cutoff value of the Wako method (11 pg/ml), the value of BDG appeared to be under this cutoff in 11 cases of breakthrough candidemia, whereas it was found to be negative in only 13 nonbreakthrough cases. The rate of the value of BDG being under the cutoff was higher in the patients with breakthrough candidemia than in those with nonbreakthrough candidemia, which was statistically significant (44% vs. 19%, p = .03).
There was no inverse correlation between BDG values and duration of prior antifungal agent use, and there were no differences in the BDG value in patients with breakthrough candidemia between different antifungal classes. In addition, there were no significant differences in BDG production among the different Candida species.
Discussion
This study reports the results of a comparison between breakthrough and nonbreakthrough candidemia in a large cohort of patients at a single institution. Candidemia was associated with high morbidity and mortality, and early initiation of antifungal therapy in patients with invasive candidiasis has been demonstrated to be crucial to reduce mortality [14, 15] . However, establishing a diagnosis proves to be very difficult, and culture-based results are often delayed [15] [16] [17] . Therefore, alternative methods for the early detection of candidemia were studied. Serological biomarkers have been investigated in several studies in order to provide early preemptive therapy. In previous studies, periodical monitoring of serum BDG levels enabled the early detection of invasive candidiasis and might be useful for starting preemptive therapy in ICU patients and in recipients of liver transplantation [18, 19] to lower mortality rates. Several diagnostic methods, such as BDG assay, Aspergillus galactomannan test, and polymerase chain reaction for detecting fungal DNA, might facilitate the earlier diagnosis of invasive fungal infections, but their role in detecting breakthrough infections in highrisk patients with hematological malignancies was less obvious, especially in patients with antifungal prophylaxis [20] . The characteristics or risk factors of breakthrough candidemia were formerly described in several reports [3] [4] [5] [21] [22] [23] , but there were no data about the usefulness of serological markers in patients with breakthrough candidemia. To the best of our knowledge, this is the first report describing the diagnostic utility of BDG in patients with breakthrough candidemia.
In previous studies, the sensitivity of serum BDG testing for invasive candidiasis ranged from 47% to 95%, and in a recent meta-analysis of eleven studies, the sensitivity was reported to be 75% [24] [25] [26] [27] . In our investigation, the sensitivity of BDG for nonbreakthrough candidemia was 81%, which is in accordance with the previous reports, but in patients with breakthrough candidemia it was only 56%. Breakthrough candidemia caused by C. parapsilosis was most frequently observed in patients receiving micafungin prophylaxis in our study, but it could also occur in patients receiving other antifungal prophylaxis. The number of patients infected with each Candida species was small, and there were no significant differences in the BDG values between patients with and without breakthrough candidemia. In addition, there were no differences in the BDG value in the patients with breakthrough candidemia receiving different antifungals. According to this result, the value of BDG being under the cutoff value is insufficient to rule out the presence of candidemia, especially in the high-risk patients with hematological disorders receiving any pretreatment antifungal agents.
It was not clear explanation as to why pretreatment with antifungal agents decreased the sensitivity of BDG in breakthrough cases. In a previous report, antifungal therapy was found to decrease the sensitivity of the Aspergillus galactomannan enzyme immunoassay. Serum galactomannan index values were reported to be correlated with fungal burden in animal models, and the overall fungal burden might be decreased with the preventive antifungal agents, so circulating galactomannan indices were insufficiently high [28] . From this perspective, pretreatment antifungal agents might decrease the overall fungal burden in breakthrough candidemia; hence the value of BDG might be significantly lower in breakthrough cases compared with nonbreakthrough cases.
Our study had the following limitations: (1) this was a retrospective analysis, so we could not sufficiently evaluate the false-positive factors of BDG in both breakthrough and nonbreakthrough cases. Several causes of false-positivity, such as human blood products (albumin or globulin), hemodialysis, surgical gauze or other materials containing glucan, and other fungus infection have been identified [29] . However, human blood products, hemodialysis, and other fungus infection, such as by Aspergillus species, were not different between the two groups, from our review of the medical records; (2) we could not collect data on BDG from all patients with candidemia. We were able to obtain data from over half of the patients with nonbreakthrough candidemia and almost all patients with breakthrough candidemia. It should be noted that clinicians did not arbitrarily select the cases in which BDG values were measured. In addition, we recently recommended that clinicians measure serum BDG values in all cases in which yeast-like cells are recovered in blood culture. Thus, there was little bias in terms of BDG data collection. Further prospective studies are needed to accumulate and analyze BDG data in patients with breakthrough candidemia; (3) the interval between obtaining blood culture specimens and measuring serum BDG values was not fixed due to the retrospective nature of this study. However, the median BDG value was found to be significantly lower in patients with breakthrough episodes than those with nonbreakthrough episodes, which included patients in whom serum BDG value was measured in the time between obtaining blood cultures specimens and within 48 hours of obtaining positive results. Further prospective studies are needed for accumulation of serum BDG data to eliminate the differences in the interval that was noted between the two groups in our study.
In summary, this is the first report describing the differences of the value of BDG between breakthrough candidemia and nonbreakthrough candidemia. According to our study, BDG alone was insufficient to detect breakthrough candidemia, and candidemia could occur under the use of antifungal agents, even when the BDG value was under the cutoff value.
